The role of post–radiation therapy fdg pet in prediction of necessity for post–radiation therapy neck dissection in locally advanced head-and-neck squamous cell carcinoma

Yao, Min; Graham, Michael M.; Hoffman, Henry T.; Smith, Russell B.; Funk, Gerry F.; Graham, Scott M.; Dornfeld, Kenneth J.; Skwarchuk, Mark W.; Menda, Yusuf; Buatti, John M.

doi:10.1016/j.ijrobp.2004.01.040

Cited by 123 publications

(77 citation statements)

References 19 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…[23][24][25][26][27][28][29][30][31] It has also been shown in several studies to have higher predictive values than CT and/or MRI, 21,27,32,33 and better than combined clinical examination and ultrasound. 31 Finally, studies have found that co-registering PET and CT (PET-CT) is even more accurate than PET alone 33,34 ( Table 1).…”

Section: 14mentioning

confidence: 99%

PET-NECK: a multicentre randomised Phase III non-inferiority trial comparing a positron emission tomography–computerised tomography-guided watch-and-wait policy with planned neck dissection in the management of locally advanced (N2/N3) nodal metastases in patients with squamous cell head and neck cancer

Mehanna

McConkey

Rahman

et al. 2017

Health Technol Assess

View full text Add to dashboard Cite

a multicentre randomised Phase III non-inferiority trial comparing a positron emission tomographycomputerised tomography-guided watch-and-wait policy with planned neck dissection in the management of locally advanced (N2/N3) nodal metastases in patients with squamous cell head and neck cancer. Health Technol Assess 2017;21(17). This journal is a member of and subscribes to the principles of the Committee on Publication Ethics (COPE) (www.publicationethics.org/). Health Technology Assessment is indexed and abstracted inEditorial contact: journals.library@nihr.ac.ukThe full HTA archive is freely available to view online at www.journalslibrary.nihr.ac.uk/hta. Print-on-demand copies can be purchased from the report pages of the NIHR Journals Library website: www.journalslibrary.nihr.ac.uk Criteria for inclusion in the Health Technology Assessment journalReports are published in Health Technology Assessment (HTA) if (1) they have resulted from work for the HTA programme, and (2) they are of a sufficiently high scientific quality as assessed by the reviewers and editors.Reviews in Health Technology Assessment are termed 'systematic' when the account of the search appraisal and synthesis methods (to minimise biases and random errors) would, in theory, permit the replication of the review by others. HTA programmeThe HTA programme, part of the National Institute for Health Research (NIHR), was set up in 1993. It produces high-quality research information on the effectiveness, costs and broader impact of health technologies for those who use, manage and provide care in the NHS. 'Health technologies' are broadly defined as all interventions used to promote health, prevent and treat disease, and improve rehabilitation and long-term care.The journal is indexed in NHS Evidence via its abstracts included in MEDLINE and its Technology Assessment Reports inform National Institute for Health and Care Excellence (NICE) guidance. HTA research is also an important source of evidence for National Screening Committee (NSC) policy decisions.For more information about the HTA programme please visit the website: http://www.nets.nihr.ac.uk/programmes/hta This reportThe research reported in this issue of the journal was funded by the HTA programme as project number 06/302/129. The contractual start date was in April 2007. The draft report began editorial review in July 2015 and was accepted for publication in June 2016. The authors have been wholly responsible for all data collection, analysis and interpretation, and for writing up their work. The HTA editors and publisher have tried to ensure the accuracy of the authors' report and would like to thank the reviewers for their constructive comments on the draft document. However, they do not accept liability for damages or losses arising from material published in this report.This report presents independent research funded by the National Institute for Health Research (NIHR). The views and opinions expressed by authors in this publication are those of the authors and do not necessarily ref...

show abstract

Section: 14mentioning

confidence: 99%

PET-NECK: a multicentre randomised Phase III non-inferiority trial comparing a positron emission tomography–computerised tomography-guided watch-and-wait policy with planned neck dissection in the management of locally advanced (N2/N3) nodal metastases in patients with squamous cell head and neck cancer

Mehanna

McConkey

Rahman

et al. 2017

Health Technol Assess

View full text Add to dashboard Cite

show abstract

“…Many studies have demonstrated the very high negative predictive value of PET/CT in posttherapy assessment of head and neck malignancy (Fig 7). 30,37,38,[43][44][45][46] Porceddu et al 38 demonstrated that a negative PET/CT result is highly reliable when PET/CT is performed at least 2-3 months after the completion of therapy. In this study, 39 eligible patients who had a residual mass in the head and neck underwent PET scanning at a median of 12 weeks (range, 8 -32 weeks) after therapy.…”

Section: Evaluation Of Therapy Responsementioning

confidence: 99%

“…50 In the setting of surveillance, numerous studies have demonstrated that 18 F-FDG-PET/CT has a relatively high sensitivity for detecting recurrent disease at the primary tumor site and regional lymph node metastases. 37,[38][39][40][41][42][43][44][45][49][50][51][52] For patients who underwent PET or PET/CT at least 12 weeks after the completion of all therapy, the reported sensitivity ranged between 90% and 100% for the detection of recurrence. Due to nonspecific inflammatory uptake, the specificity of PET and PET/CT is between 63% and 94%, and a tissue biopsy or shortinterval repeat scanning is warranted.…”

Section: Evaluation Of Recurrence and Surveillancementioning

confidence: 99%

Fluorodeoxyglucose–Positron-Emission Tomography Imaging of Head and Neck Squamous Cell Cancer

Subramaniam

Truong

Peller

et al. 2009

AJNR Am J Neuroradiol

107

View full text Add to dashboard Cite

SUMMARY:The hybrid technique of PET/CT has significantly impacted the imaging and management of HNSCC since its introduction in 2001 and has become the technique of choice for imaging of this cancer. Diagnostic FDG-PET/CT is useful for identification of an unknown primary tumor, delineation of extent of primary tumor, detection of regional lymph node involvement even in a normal-sized node, detection of distant metastases and occasional synchronous primary tumor, assessment of therapy response, and long-term surveillance for recurrence and metastases. The role of PET/CT is evolving in radiation therapy planning. Combined diagnostic PET/CT provides the best anatomic and metabolic in vivo information for the comprehensive management of HNSCC.ABBREVIATIONS: CR ϭ complete response; DCT ϭ contrast enhanced diagnostic CT;18 F ϭ fluorine-18; FDG ϭ fluorodeoxyglucose; FDG-PET ϭ fluorodeoxyglucose-positron-emission tomography; FNA ϭ fine-needle aspiration; GTV ϭ gross tumor volume; HNSCC ϭ head and neck squamous cell carcinomas; IMRT ϭ intensity modulated radiation therapy; M ϭ metastasis; N ϭ node; PET ϭ positron-emission tomography; PTV ϭ planning target volume; RD ϭ residual disease; SCC ϭ squamous cell carcinoma; SUV ϭ standard uptake value; SUV max ϭ maximum SUV; T ϭ tumor M ore than 40,000 people are diagnosed with head and neck cancer each year in the United States.1 The overall annual mortality rate for this cancer in the United States is 23%, and the 5-year survival rate is 56%.1-3 More than 80% of early-stage tumors are cured, but nearly one-half of patients have evidence of advanced local disease or lymph node metastases at the time of diagnosis. Surgery and radiation therapy, either alone or in combination with chemotherapy, are used for definitive locoregional treatment of head and neck cancers. For patients with advancedstage and high-risk features, postoperative chemoradiation improves locoregional control and overall survival. 4,5 Cross-sectional imaging with CT and MR imaging is commonly used for tumor staging and may allow detection of subcentimeter lesions. Locoregional lymph node metastases have a major impact on survival. Patients with lymph-node involvement have a worse prognosis (approximately 30%) than patients without lymph node involvement (Ͼ50% 5-year survival). 6,7 PET using the radiotracer 18 F FDG is widely used to evaluate patients with HNSCC. The hybrid technique, PET/CT, provides anatomic and functional information and can be performed as PET and DCT with intravenous contrast-enhancement (PET/ DCT) or PET and noncontrast CT (PET/CT) for attenuation correction and anatomic localization. PET/CT is useful for identification of an unknown primary tumor, delineation of the extent of regional lymph node involvement, detection of distant metastases and occasional synchronous primary tumor, radiation-therapy planning, assessing therapy response, and long-term surveillance for recurrence and metastases.PET/CT Protocols PET/CT imaging was developed to improve PET imaging by expediting attenuation c...

show abstract

“…The value of follow-up PET/CT for patient outcome, and the added value to the clinical assessment, are not fully established. Previous studies (11,(19)(20)(21) have shown the prognostic significance of follow-up PET or PET/CT performed within 1 y after the completion of therapy. A recent study demonstrated the temporal patterns of HNSCC recurrence with 18 F-FDG PET/CT and concluded that PET/CT detected 73 asymptomatic recurrences in 110 patients with recurrence, with 95% of the observed recurrences being detected within 24 mo (22).…”

mentioning

confidence: 99%

Addition of ¹⁸F-FDG PET/CT to Clinical Assessment Predicts Overall Survival in HNSCC: A Retrospective Analysis with Follow-up for 12 Years

et al. 2013

View full text Add to dashboard Cite

18 F-FDG PET/CT is used in the follow-up of patients with head and neck squamous cell cancer (HNSCC). However, its impact on clinical decision making and patient outcome is not fully established. The objective of this study was to determine the prognostic value of 18 F-FDG PET/CT for overall survival (OS) of HNSCC patients when performed in addition to clinical assessment between 4 and 24 mo after treatment. Methods: This was a retrospective study at a single tertiary center. The institutional review board approved this study, and the requirement to obtain informed consent was waived. The study included 134 biopsy-proven HNSCC patients with 227 followup PET/CT scans. The primary outcome measure was OS. Median follow-up was 40 mo (range, 7-145 mo). Survival is presented as Kaplan-Meier plots with Mantel-Cox log-rank test. The multivariate Cox model included clinical covariates. Results: Of the 227 PET/CT scans, 41 (18%) were positive for tumor and 186 (82%) were negative for tumor. PET/CT identified recurrence in 5% (9/194) of scans performed without prior clinical concern and ruled out tumor in 51.5% (17/33) of scans performed to evaluate clinical suspicion or uncertainty of recurrence. The median survival of PET-positive and -negative groups from the date of the scan was 20 and 30.5 mo, respectively (P , 0.0001). There was a significant difference in OS from the scan date between patients who had a positive PET/CT result for tumor and those who had a negative result (log-rank, P , 0.0001), with a hazard ratio of 29.74. Human papillomavirus status (P 5 0.001) and PET/CT result (P 5 0.04) were the only factors significantly associated with OS, adjusted for all other covariates. Conclusion: 18 F-FDG PET/CT performed between 4 and 24 mo after treatment adds value to clinical assessment at the time of the study, especially when there is clinical suspicion or uncertainty, and can serve as a prognostic marker of OS in HNSCC.

show abstract

The role of post–radiation therapy fdg pet in prediction of necessity for post–radiation therapy neck dissection in locally advanced head-and-neck squamous cell carcinoma

Cited by 123 publications

References 19 publications

Fluorodeoxyglucose–Positron-Emission Tomography Imaging of Head and Neck Squamous Cell Cancer

Addition of ¹⁸F-FDG PET/CT to Clinical Assessment Predicts Overall Survival in HNSCC: A Retrospective Analysis with Follow-up for 12 Years

Contact Info

Product

Resources

About

The role of post–radiation therapy fdg pet in prediction of necessity for post–radiation therapy neck dissection in locally advanced head-and-neck squamous cell carcinoma

Cited by 123 publications

References 19 publications

Fluorodeoxyglucose–Positron-Emission Tomography Imaging of Head and Neck Squamous Cell Cancer

Addition of 18F-FDG PET/CT to Clinical Assessment Predicts Overall Survival in HNSCC: A Retrospective Analysis with Follow-up for 12 Years

Contact Info

Product

Resources

About

Addition of ¹⁸F-FDG PET/CT to Clinical Assessment Predicts Overall Survival in HNSCC: A Retrospective Analysis with Follow-up for 12 Years